FLOW trial (revision 3)
Old revision·21:12, 9 Oct 2024·LotTraceLuka
| FLOW trial | |
|---|---|
| Drug | Semaglutide 1.0 mg weekly |
| Population | Type 2 diabetes with chronic kidney disease |
| Participants | 3,533 |
| Primary result | Kidney outcome HR 0.76 (95% CI 0.66–0.88) |
| Topic infobox · conventions | |
FLOW was a randomised, double-blind, placebo-controlled trial of weekly semaglutide 1.0 mg in 3,533 adults with type 2 diabetes and chronic kidney disease. It was stopped early for efficacy on the recommendation of its data monitoring committee.[1]
The primary composite comprised onset of kidney failure, a sustained fall of at least 50% in estimated glomerular filtration rate, or death from kidney or cardiovascular causes. It occurred less often on semaglutide, hazard ratio 0.76 (95% CI 0.66–0.88).[1]
Design
[edit]Participants had type 2 diabetes with an estimated glomerular filtration rate and albumin-to-creatinine ratio within defined ranges, and were on maximum tolerated renin–angiotensin system blockade. The trial therefore tested semaglutide added to established renal protection rather than in its place.[1]
The dose studied was 1.0 mg weekly — the type 2 diabetes dose, not the 2.4 mg obesity dose. As elsewhere in this field, results at one dose do not transfer to another.[2]
References
- ^ a b c Perkovic V, Tuttle KR, Rossing P, et al. "Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes." New England Journal of Medicine 391(2):109–121 (2024). DOI:10.1056/NEJMoa2403347. PMID 38785209.
- ^ Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." New England Journal of Medicine 389(24):2221–2232 (2023). PMID 37952131.